Literature DB >> 16518601

Treatment of acute myeloid leukemia in a Jehovah's Witness.

Shail Dalal, Manoranjan Boddapati, Mary N Lowery, Diana M Veillon, Jonathan Glass, Reinhold Munker.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16518601     DOI： 10.1007/s00277-006-0087-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.

Authors:  Judit Demeter; Ildiko Istenes; Anikó Fodor; Melinda Paksi; Peter Dombi; Erika Valasinyószki; Judit Csomor; András Matolcsy; Zsolt G Nagy
Journal:  Pathol Oncol Res       Date:  2010-07-14       Impact factor: 3.201

Review 2.  Reflections on Cultural Preferences and Internal Medicine: The Case of Jehovah's Witnesses and the Changing Thresholds for Blood Transfusions.

Authors:  Iftach Sagy; Alan Jotkowitz; Leonid Barski
Journal:  J Relig Health       Date:  2017-04

3.  A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.

Authors:  Yumi Yamamoto; Akihito Kawashima; Eri Kashiwagi; Kiyoyuki Ogata
Journal:  Case Rep Hematol       Date:  2014-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.